Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle - PubMed

Affiliations

• PMID: 12006582
• DOI: 10.1074/jbc.M200958200

Free article

Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle

Chunli Yu et al. J Biol Chem. 2002.

Free article

Abstract

Recent studies have demonstrated that fatty acids induce insulin resistance in skeletal muscle by blocking insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase (PI3-kinase). To examine the mechanism by which fatty acids mediate this effect, rats were infused with either a lipid emulsion (consisting mostly of 18:2 fatty acids) or glycerol. Intracellular C18:2 CoA increased in a time-dependent fashion, reaching an approximately 6-fold elevation by 5 h, whereas there was no change in the concentration of any other fatty acyl-CoAs. Diacylglycerol (DAG) also increased transiently after 3-4 h of lipid infusion. In contrast there was no increase in intracellular ceramide or triglyceride concentrations during the lipid infusion. Increases in intracellular C18:2 CoA and DAG concentration were associated with protein kinase C (PKC)-theta activation and a reduction in both insulin-stimulated IRS-1 tyrosine phosphorylation and IRS-1 associated PI3-kinase activity, which were associated with an increase in IRS-1 Ser(307) phosphorylation. These data support the hypothesis that an increase in plasma fatty acid concentration results in an increase in intracellular fatty acyl-CoA and DAG concentrations, which results in activation of PKC-theta leading to increased IRS-1 Ser(307) phosphorylation. This in turn leads to decreased IRS-1 tyrosine phosphorylation and decreased activation of IRS-1-associated PI3-kinase activity resulting in decreased insulin-stimulated glucose transport activity.

Similar articles

• Female rats do not exhibit free fatty acid-induced insulin resistance.

  Hevener A, Reichart D, Janez A, Olefsky J. Hevener A, et al. Diabetes. 2002 Jun;51(6):1907-12. doi: 10.2337/diabetes.51.6.1907. Diabetes. 2002. PMID: 12031980

• Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade.

  Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI. Griffin ME, et al. Diabetes. 1999 Jun;48(6):1270-4. doi: 10.2337/diabetes.48.6.1270. Diabetes. 1999. PMID: 10342815

• Glucosamine infusion in rats rapidly impairs insulin stimulation of phosphoinositide 3-kinase but does not alter activation of Akt/protein kinase B in skeletal muscle.

  Kim YB, Zhu JS, Zierath JR, Shen HQ, Baron AD, Kahn BB. Kim YB, et al. Diabetes. 1999 Feb;48(2):310-20. doi: 10.2337/diabetes.48.2.310. Diabetes. 1999. PMID: 10334307

• Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats.

  Hevener AL, Reichart D, Janez A, Olefsky J. Hevener AL, et al. Diabetes. 2001 Oct;50(10):2316-22. doi: 10.2337/diabetes.50.10.2316. Diabetes. 2001. PMID: 11574414

• Muscular diacylglycerol metabolism and insulin resistance.

  Timmers S, Schrauwen P, de Vogel J. Timmers S, et al. Physiol Behav. 2008 May 23;94(2):242-51. doi: 10.1016/j.physbeh.2007.12.002. Epub 2007 Dec 14. Physiol Behav. 2008. PMID: 18207474 Review.

Cited by

• CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance.

  Cantley JL, Yoshimura T, Camporez JP, Zhang D, Jornayvaz FR, Kumashiro N, Guebre-Egziabher F, Jurczak MJ, Kahn M, Guigni BA, Serr J, Hankin J, Murphy RC, Cline GW, Bhanot S, Manchem VP, Brown JM, Samuel VT, Shulman GI. Cantley JL, et al. Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1869-74. doi: 10.1073/pnas.1219456110. Epub 2013 Jan 9. Proc Natl Acad Sci U S A. 2013. PMID: 23302688 Free PMC article.

• Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease.

  Henin G, Loumaye A, Leclercq IA, Lanthier N. Henin G, et al. JHEP Rep. 2023 Nov 14;6(2):100963. doi: 10.1016/j.jhepr.2023.100963. eCollection 2024 Feb. JHEP Rep. 2023. PMID: 38322420 Free PMC article. Review.

• Modulation of glucose transporter protein by dietary flavonoids in type 2 diabetes mellitus.

  Hajiaghaalipour F, Khalilpourfarshbafi M, Arya A. Hajiaghaalipour F, et al. Int J Biol Sci. 2015 Mar 19;11(5):508-24. doi: 10.7150/ijbs.11241. eCollection 2015. Int J Biol Sci. 2015. PMID: 25892959 Free PMC article. Review.

• Glycosphingolipids in Diabetes, Oxidative Stress, and Cardiovascular Disease: Prevention in Experimental Animal Models.

  Balram A, Thapa S, Chatterjee S. Balram A, et al. Int J Mol Sci. 2022 Dec 6;23(23):15442. doi: 10.3390/ijms232315442. Int J Mol Sci. 2022. PMID: 36499769 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • GlyGen glycoinformatics resource